Merck (MRK) traded lower Tuesday as the market repriced the company’s 2026 earnings power and the durability of its vaccine contribution, with particular attention on Gardasil. Merck’s 2026 guidance has been viewed as conservative versus prior expectations, and the company has communicated that its outlook does not assume any Gardasil shipments to China—keeping a major uncertainty in place and pressuring sentiment as investors look for a clearer inflection point in the second-largest market for the HPV franchise. (finance.yahoo.com)

Gardasil has been a key growth engine, and the company’s decision to pause shipments to China—then extend that pause—has had an outsized impact on how investors model near-term revenue and margin. The market continues to treat the China restart timeline as a swing factor, especially with local competitive dynamics and uneven demand recovery cited as headwinds. (investing.com)

Near-term attention shifts to Merck’s next quarterly report and management commentary on Gardasil inventory and demand signals in China, plus any clarity on whether shipments could resume later in 2026. Investors will also watch how much incremental growth comes from newer products highlighted as supports to the broader portfolio, as the company works to diversify beyond its largest franchises. (markets.financialcontent.com)

Today’s drop reflects a risk-off reset around 2026 visibility rather than a single discrete headline, with the core issue being that Merck’s outlook bakes in no China Gardasil shipments and therefore leaves limited near-term upside until there is evidence of a restart. Without a cleaner catalyst, the stock can remain sensitive to incremental news on China demand, competitive pressures, and any guidance updates.